Financial disclosure by clinical investigators; correction--FDA. Final rule; correction
Related Experiment Video
Updated: Oct 23, 2026

Working with Human Tissues for Translational Cancer Research
Published on: November 26, 2015
Abstract:
The Food and Drug Administration (FDA) is correcting a final rule that appeared in the Federal Register of February 2, 1998 (63 FR 5233). The document issued regulations requiring the sponsor of any drug, including a biological product, or device marketing application (applicant), to submit certain information covering the compensation to, and financial interests of, any clinical investigator conducting certain clinical studies. The document was published with an error. This document corrects that error.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinically Relevant Drug Product Specifications: Methods of Establishment
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Preclinical Development: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
